Editas Medicine Inc (NASDAQ: EDIT) kicked off on Monday, down -2.46% from the previous trading day, before settling in for the closing price of $2.44. Over the past 52 weeks, EDIT has traded in a range of $2.30-$11.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 101.57% over the past five years. While this was happening, its average annual earnings per share was recorded -28.82%. With a float of $81.77 million, this company’s outstanding shares have now reached $82.55 million.
Let’s look at the performance matrix of the company that is accounted for 265 employees. In terms of profitability, gross margin is 90.46%, operating margin of -370.03%, and the pretax margin is -340.96%.
Editas Medicine Inc (EDIT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.94%, while institutional ownership is 67.85%. The most recent insider transaction that took place on Sep 04 ’24, was worth 1,774. In this transaction EVP, CHIEF MEDICAL OFFICER of this company sold 518 shares at a rate of $3.42, taking the stock ownership to the 133,895 shares. Before that another transaction happened on Sep 04 ’24, when Company’s CEO sold 1,555 for $3.42, making the entire transaction worth $5,325. This insider now owns 313,724 shares in total.
Editas Medicine Inc (EDIT) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.23 earnings per share (EPS), higher than consensus estimate (set at -0.48) by 0.25. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -28.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.70% during the next five years compared to 2.88% growth over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Take a look at Editas Medicine Inc’s (EDIT) current performance indicators. Last quarter, stock had a quick ratio of 3.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.56, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -2.26 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Editas Medicine Inc (NASDAQ: EDIT) saw its 5-day average volume 3.14 million, a positive change from its year-to-date volume of 1.96 million. As of the previous 9 days, the stock’s Stochastic %D was 10.04%. Additionally, its Average True Range was 0.21.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 2.13%, which indicates a significant decrease from 7.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.99% in the past 14 days, which was lower than the 69.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.17, while its 200-day Moving Average is $5.17. Nevertheless, the first resistance level for the watch stands at $2.49 in the near term. At $2.60, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.67. If the price goes on to break the first support level at $2.31, it is likely to go to the next support level at $2.24. Assuming the price breaks the second support level, the third support level stands at $2.13.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
The company with the Market Capitalisation of 202.27 million has total of 82,548K Shares Outstanding. Its annual sales at the moment are 78,120 K in contrast with the sum of -153,220 K annual income. Company’s last quarter sales were recorded 60 K and last quarter income was -62,140 K.
